ProShare Advisors LLC Cuts Position in Humana Inc. $HUM

ProShare Advisors LLC reduced its holdings in shares of Humana Inc. (NYSE:HUM) by 23.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,194 shares of the insurance provider’s stock after selling 6,408 shares during the quarter. ProShare Advisors LLC’s holdings in Humana were worth $5,514,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in Humana by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 14,199,096 shares of the insurance provider’s stock worth $3,471,395,000 after purchasing an additional 226,224 shares during the period. Dodge & Cox boosted its position in shares of Humana by 5.6% in the second quarter. Dodge & Cox now owns 11,352,920 shares of the insurance provider’s stock worth $2,775,562,000 after buying an additional 597,705 shares during the period. State Street Corp grew its stake in shares of Humana by 1.1% in the second quarter. State Street Corp now owns 5,377,390 shares of the insurance provider’s stock valued at $1,319,334,000 after buying an additional 58,094 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Humana by 273.2% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,488,261 shares of the insurance provider’s stock valued at $907,541,000 after buying an additional 2,553,509 shares during the period. Finally, Geode Capital Management LLC lifted its position in Humana by 1.9% during the 2nd quarter. Geode Capital Management LLC now owns 3,130,829 shares of the insurance provider’s stock worth $762,233,000 after acquiring an additional 57,267 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Price Performance

Shares of HUM stock opened at $183.92 on Friday. The firm has a fifty day moving average of $244.65 and a two-hundred day moving average of $260.85. The firm has a market cap of $22.12 billion, a P/E ratio of 18.73, a P/E/G ratio of 1.99 and a beta of 0.44. Humana Inc. has a 1-year low of $169.61 and a 1-year high of $315.35. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.00 and a quick ratio of 2.02.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) EPS for the quarter, topping the consensus estimate of ($4.01) by $0.05. The business had revenue of $32.64 billion for the quarter, compared to analysts’ expectations of $32.08 billion. Humana had a net margin of 0.92% and a return on equity of 11.43%. The company’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same quarter last year, the company posted ($2.16) earnings per share. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. As a group, research analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on HUM shares. Guggenheim lowered their price objective on shares of Humana from $312.00 to $252.00 and set a “buy” rating for the company in a research report on Thursday. Wolfe Research upped their target price on shares of Humana from $300.00 to $325.00 and gave the company an “outperform” rating in a research note on Thursday, January 8th. Robert W. Baird dropped their price target on shares of Humana from $280.00 to $264.00 and set a “neutral” rating on the stock in a research note on Thursday, December 11th. Zacks Research lowered shares of Humana from a “hold” rating to a “strong sell” rating in a report on Thursday, January 1st. Finally, Barclays restated an “underperformer” rating on shares of Humana in a research note on Monday, January 5th. Seven investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and five have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $239.46.

Key Stories Impacting Humana

Here are the key news stories impacting Humana this week:

• Positive Sentiment: CenterWell (Humana’s healthcare services unit) closed the acquisition of MaxHealth, adding a sizable Florida primary‑care network (~82 owned/affiliated clinics and >80,000 patients in value‑based programs) which expands Humana’s senior-focused, value‑based primary care footprint and accelerates revenue and membership growth in higher-value care. CenterWell Completes Acquisition of MaxHealth
• Positive Sentiment: Management signals more primary‑care deals may be coming (CEO remarks and media reports about a potential ~$1B strategic push), reinforcing the company’s strategy to grow value‑based care capacity — a long‑term growth catalyst if Humana can scale clinics and convert MA members to higher‑margin care. Humana CEO hints at upcoming primary care deal
• Neutral Sentiment: Jefferies cut its price target (from $310 to $235) but kept a Buy rating, reflecting disagreement among analysts on Humana’s growth vs. margin tradeoff — some firms still see upside despite lower near‑term earnings visibility. Jefferies price target change
• Negative Sentiment: Several major analysts materially lowered price targets and trimmed estimates (TD Cowen to $173 Hold; JPMorgan to $180 Neutral; Evercore, Cantor, Leerink also cut targets), reflecting concern that Medicare Advantage cost pressures, lower quality (STAR) ratings, and a cautious 2026 earnings guide will weigh on near‑term profitability. TD Cowen PT cut
• Negative Sentiment: Humana reported a fourth‑quarter loss and issued a cautious 2026 outlook (management flagged sharply lower near‑term earnings as Medicare Advantage membership surges but margins remain under pressure), which prompted analysts to slash forecasts and is the primary fundamental reason for downward pressure on the stock. Humana stock falls on disappointing earnings forecast

Humana Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.